A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
PART I Company Overview Baxter International Inc., through our subsidiaries, provides a broad portfolio of essential healthcare products, including sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices. These products are used by hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors’ offices, kidney dialysis centers and patients at home under physician supervision. Our global footprint and the critical nature of our products and services play a key role in expanding access to healthcare in emerging and developed countries.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 11.2B | 11.2B | 10.6B | 10.4B | 10.1B | 12.8B |
| Net Income | -957M | -957M | -649M | 2.7B | -2.4B | 1.3B |
| EPS | $-1.87 | $-1.87 | $-1.27 | $5.23 | $-4.83 | $2.53 |
| Free Cash Flow | 332M | 332M | 573M | 1.3B | 591M | 1.5B |
| ROIC | -1.8% | -3.3% | - | 13.6% | -11.5% | 6.8% |
| Gross Margin | 30.1% | 30.1% | 37.5% | 40.1% | 50.4% | 39.9% |
| Debt/Equity | 1.58 | 1.58 | 2.32 | 1.67 | 2.93 | 2.07 |
| Dividends/Share | $0.68 | $0.52 | $1.04 | $1.16 | $1.15 | $1.09 |
| Operating Income | -308M | -308M | - | 707M | -2.2B | 1.7B |
| Operating Margin | -2.7% | -2.7% | - | 6.8% | -22.3% | 13.4% |
| ROE | -15.6% | -14.6% | -9.3% | 31.6% | -41.7% | 14.1% |
| Shares Outstanding | 512M | 512M | 511M | 508M | 504M | 508M |
BAXTER INTERNATIONAL INC passes 2 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 27.2x vs a median of 26.6x. The company's 5-year average ROIC is 1.4% with a gross margin of 39.6%. Total shareholder yield (dividends) is 3.9%. At current prices, the estimated annualized return to fair value is -13.1%.
BAXTER INTERNATIONAL INC (BAX) has a 5-year average return on invested capital (ROIC) of 1.4%. This is below average and may indicate limited pricing power.
BAXTER INTERNATIONAL INC (BAX) has a market capitalization of $9.0B. It is classified as a mid-cap stock.
Yes, BAXTER INTERNATIONAL INC (BAX) pays a dividend with a trailing twelve-month yield of 3.86%.
BAXTER INTERNATIONAL INC (BAX) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
BAXTER INTERNATIONAL INC (BAX) reported annual revenue of $11.2 billion in its most recent fiscal year, based on SEC EDGAR filings.
BAXTER INTERNATIONAL INC (BAX) has a net profit margin of -8.5%. The company is currently unprofitable.
BAXTER INTERNATIONAL INC (BAX) generated $332 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
BAXTER INTERNATIONAL INC (BAX) has a debt-to-equity ratio of 1.58. This indicates higher leverage, which may increase financial risk.
BAXTER INTERNATIONAL INC (BAX) reported earnings per share (EPS) of $-1.87 in its most recent fiscal year.
BAXTER INTERNATIONAL INC (BAX) has a return on equity (ROE) of -14.6%. A negative ROE may indicate losses or negative equity.
BAXTER INTERNATIONAL INC (BAX) has a 5-year average gross margin of 39.6%. This indicates decent pricing power.
The Ledger Terminal provides 19 years of financial data for BAXTER INTERNATIONAL INC (BAX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
BAXTER INTERNATIONAL INC (BAX) has a book value per share of $11.98, based on its most recent annual SEC filing.